Received Mar 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
second Shingrix dose was 1 week late; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received in AUG-2024). On 24-FEB-2025, the patient received the 2nd dose of Shingrix. On 24-FEB-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: second Shingrix dose was 1 week late). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 24-FEB-2025 The reporter was the patient and reported the second Shingrix dose was 1 week late. The reporter said her pharmacy did not call her that she needed the second dose until 21st February 2025. The reporter received the second Shingrix dose on 25th February 2025 which led to lengthening of vaccination schedule. The reporter did not had the date of the first dose of Shingrix other than it was in August 2024. The pharmacist told her since she was a week late that this would be considered her first dose and she would have to return to get another dose.